^
Association details:
| Biomarker: | SPP1 elevation |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
Published date:
03/30/2023
Excerpt:
This prospective multicenter study enrolled 70 patients with uHCC who received atezolizumab and bevacizumab (Atez/Bev)….Among these, pretreatment OPN levels were higher in PD group than in non-PD group for Atez/Bev….High serum OPN levels were associated with poor response to Atez/Bev in patients with uHCC.
DOI:
10.1007/s00535-023-01985-w
